Search

everythinglearnresearchcommunity

for

Search:↓

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

A woman with severe angioedema improved significantly after treatment with rituximab.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Panitumumab can cause excessive ear hair growth.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

A patient's grey hair regained color during treatment with adalimumab.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Ki-67 levels do not predict treatment response in triple-negative breast cancer.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.